Molgramostim review pushed to November: what Savara’s FDA delay means for autoimmune PAP
Savara’s molgramostim FDA review was extended to November 22, 2026. Read what this means for autoimmune PAP, launch timing, and regulatory risk.
Pharma & Biotech
Medical Devices & Diagnostics
What SurGenTec’s TiLink navigation clearance means for surgeons using minimally invasive SI joint fusion systems
SurGenTec won FDA 510(k) clearance for TiLink navigation instruments. Read what this means for SI joint fusion adoption, workflow, and competition.
Medical Devices & Diagnostics
Can Covalon Technologies convert IV contamination education into adoption of VALGuard and CovaClear?
Covalon Technologies is gaining momentum in vascular access and wound care. Read why its latest milestones could shape medtech growth next.
Pharma & Biotech
How Regenerating Skin Nectar with TriHex+ could strengthen Galderma’s aesthetics ecosystem
Galderma has launched Regenerating Skin Nectar with TriHex+. Read why this matters for peri-procedural skincare, clinics, and regenerative aesthetics.
Medical Devices & Diagnostics
CareDx divests Lab Products for $170m as core transplant diagnostics gains momentum
CareDx is selling its Lab Products business for $170 million. Read what the deal means for transplant diagnostics, growth focus, and execution risk.
Pharma & Biotech
Why CUE-401’s IMMUNOLOGY2026 data could matter for autoimmune drug pipelines
Cue Biopharma, Inc. unveils new CUE-401 data. Find out what this means for autoimmune therapy development and the regulatory path ahead.
Pharma & Biotech
Can Immutep Limited convert orphan designation into a credible late-stage oncology program?
FDA orphan drug designation gives Immutep Limited a new sarcoma pathway. Find out why eftilagimod alfa could reshape its oncology strategy.
Pharma & Biotech
How Boehringer Ingelheim and Zai Lab are advancing a two-pronged DLL3 attack in SCLC
Can dual DLL3 targeting improve SCLC outcomes? Read PDN’s deep analysis of the Boehringer Ingelheim and Zai Lab collaboration today.
Features & Analysis
Can Teva Pharmaceutical Industries Ltd.’s Home Ground platform reshape schizophrenia support beyond medication?
Read how Teva Pharmaceutical Industries Ltd.’s Home Ground may reshape schizophrenia support, adherence, and care pathways. Discover what changes next.
Pharma & Biotech
What Grace Therapeutics’ STRIVE-ON data may change in neurocritical care
Grace Therapeutics’ GTx-104 heads to AAN 2026 just before FDA decision day. Find out what this could change in neurocritical care.